Nebulized step‑down budesonide vs. fluticasone in infantile asthma: A retrospective cohort study Corrigendum in /10.3892/etm.2020.9140

Wu,Zhimin; Bian,Xiangli; Hui,Lei; Zhang,Jinping

doi:10.3892/etm.2019.8401

Nebulized step‑down budesonide vs. fluticasone in infantile asthma: A retrospective cohort study

Corrigendum in: /10.3892/etm.2020.9140

Authors:
- Zhimin Wu
- Xiangli Bian
- Lei Hui
- Jinping Zhang
View Affiliations

Affiliations: Department of Pediatrics, Shanghai Sixth People’s Hospital East Affiliated to Shanghai University of Medicine & Health Sciences, Shanghai 201306, P.R. China
Published online on: December 31, 2019 https://doi.org/10.3892/etm.2019.8401
Pages: 1665-1672
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The United States Food and Drug Administration has approved budesonide in infantile asthma but nebulization of infants under budesonide has the risk of relapse of asthma. The objective of the present study was to compare the effectiveness and safety of fluticasone step‑down treatment with budesonide step‑down treatment in infantile asthma. The data of 778 infants with confirmed asthma were included in the analysis. Infants who had received nebulized 500 µg budesonide twice daily for 6 weeks followed by 250 µg budesonide twice daily for 6 weeks were included in the BS group (n=389), while infants who had received nebulized 250 µg fluticasone twice daily for 6 weeks followed by 125 µg fluticasone twice daily for 6 weeks were included in the FC group (n=389). The data of lung function tests and a safety study were collected and analyzed. Budesonide treatment achieved a reduced specific airway resistance (sRaw; 1.28±0.11 vs. 1.21±0.10 kPa/sec; P<0.0001, q=13.45) and improved forced expiratory volume in 1 sec (FEV1; 0.977±0.068 vs. 0.997±0.085 l/sec; P<0.0001, q=5.54). In addition, fluticasone treatment achieved a reduced sRaw (1.27±0.1 vs. 1.23±0.11 kPa/sec, P<0.0001, q=7.39) and improved FEV1 (0.971±0.069 vs. 0.992±0.085 l/sec; P=0.0003, q=5.46). Of note, the efficacy of budesonide to reduce sRaw (P=0.008, q=3.69) and improve FEV1 (P<0.0001, q=6.93) was greater than that of fluticasone. The budesonide treatment group had more post‑treatment symptom‑free days than the fluticasone treatment group (165.56±23.15 vs. 112.21±9.45 days; P<0.0001). The step‑down approach of budesonide nebulization may better support the functional and clinical outcomes with an increased number of post‑treatment symptom‑free days compared with fluticasone in infantile asthma (level of evidence, 3).

View Figures

View References

1	Sears MR: Lung function decline in asthma. Eur Respir J. 30:411–413. 2007. View Article : Google Scholar : PubMed/NCBI
2	Yoshihara S: Early intervention for infantile and childhood asthma. Expert Rev Clin Immunol. 6:247–255. 2010. View Article : Google Scholar : PubMed/NCBI
3	Murray CS, Woodcock A, Langley SJ, Morris J and Custovic A; IFWIN study team, : Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): Double-blind, randomised, controlled study. Lancet. 368:754–762. 2006. View Article : Google Scholar : PubMed/NCBI
4	Martinez FD: Inhaled corticosteroids and asthma prevention. Lancet. 368:708–710. 2006. View Article : Google Scholar : PubMed/NCBI
5	Zhou X, Hong J, Cheng H, Xie J, Yang J, Chen Q, He S, Li Y, Zhou X and Li C: Budesonide suspension nebulization treatment in Chinese pediatric patients with cough variant asthma: A multi-center observational study. J Asthma. 53:532–537. 2016. View Article : Google Scholar : PubMed/NCBI
6	Boulet LP, FitzGerald JM and Reddel HK: The revised 2014 GINA strategy report: Opportunities for change. Curr Opin Pulm Med. 21:1–7. 2015. View Article : Google Scholar : PubMed/NCBI
7	Merkus PJ and de Jongste JC: Inhaled corticosteroids in wheezy infants. Am J Respir Crit Care Med. 172:1058–1059. 2005. View Article : Google Scholar : PubMed/NCBI
8	Pelaia G, Vatrella A, Busceti MT, Fabiano F, Terracciano R, Matera MG and Maselli R: Molecular and cellular mechanisms underlying the therapeutic effects of budesonide in asthma. Pulm Pharmacol Ther. 40:15–21. 2016. View Article : Google Scholar : PubMed/NCBI
9	Melani AS: Nebulized corticosteroids in asthma and COPD. An Italian appraisal. Respir Care. 57:1161–1174. 2012. View Article : Google Scholar : PubMed/NCBI
10	Teper AM, Kofman CD, Szulman GA, Vidaurreta SM and Maffey AF: Fluticasone improves pulmonary function in children under 2 years old with risk factors for asthma. Am J Respir Crit Care Med. 171:587–590. 2005. View Article : Google Scholar : PubMed/NCBI
11	De Benedictis FM, Del Giudice MM, Vetrella M, Tressanti F, Tronci A, Testi R and Dasic G; Flic12 Study Group, : Nebulized fluticasone propionate vs. budesonide as adjunctive treatment in children with asthma exacerbation. J Asthma. 42:331–336. 2005. View Article : Google Scholar : PubMed/NCBI
12	Saddi V, Beggs S, Bennetts B, Harrison J, Hime N, Kapur N, Lipsett J, Nogee LM, Phu A, Suresh S, et al: Childhood interstitial lung diseases in immunocompetent children in Australia and New Zealand: A decade's experience. Orphanet J Rare Dis. 12:1332017. View Article : Google Scholar : PubMed/NCBI
13	Urbankowski T and Przybyłowski T: Methods of airway resistance assessment. Pneumonol Alergol Pol. 84:134–141. 2016. View Article : Google Scholar : PubMed/NCBI
14	Lai SH, Liao SL, Yao TC, Tsai MH, Hua MC, Chiu CY, Yeh KW and Huang JL: Raised-volume forced expiratory flow-volume curve in healthy Taiwanese infants. Sci Rep. 7:63142017. View Article : Google Scholar : PubMed/NCBI
15	Burman J, Lukkarinen H, Elenius V, Remes S, Kuusela T and Jartti T: Eucapnic voluntary hyperventilation test in children. Clin Physiol Funct Imaging. 38:718–720. 2018. View Article : Google Scholar : PubMed/NCBI
16	American Thoracic Society; European Respiratory Society, . ATS/ERS statement: Raised volume forced expirations in infants: Guidelines for current practice. Am J Respir Crit Care Med. 172:1463–1471. 2005. View Article : Google Scholar : PubMed/NCBI
17	Cetinkaya F, Kayiran P, Memioglu N, Tarim OF, Eren N and Erdem E: Effects of nebulized corticosteroids therapy on hypothalamic-pituitary-adrenal axis in young children with recurrent or persistent wheeze. Pediatr Allergy Immunol. 19:773–776. 2008. View Article : Google Scholar : PubMed/NCBI
18	Zou YX, Zhang J, Ma C, Li J, Zai J and Guo YS: Clinical efficacy of montelukast sodium in treating infantile wheezing. Eur Rev Med Pharmacol Sci. 18:775–780. 2014.PubMed/NCBI
19	Saito M, Kikuchi Y, Kawarai Lefor A and Hoshina M: High-dose nebulized budesonide is effective for mild asthma exacerbations in children under 3 years of age. Eur Ann Allergy Clin Immunol. 49:22–27. 2017.PubMed/NCBI
20	Rachelefsky G: Inhaled corticosteroids and asthma control in children: Assessing impairment and risk. Pediatrics. 123:353–366. 2009. View Article : Google Scholar : PubMed/NCBI
21	Rank MA, Johnson R, Branda M, Herrin J, van Houten H, Gionfriddo MR and Shah ND: Long-term outcomes after stepping down asthma controller medications: A claims-based, time-to-event analysis. Chest. 148:630–639. 2015. View Article : Google Scholar : PubMed/NCBI
22	Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K and Fagerås M: Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: A post-hoc analysis of three randomised trials. Lancet Respir Med. 6:117–126. 2018. View Article : Google Scholar : PubMed/NCBI
23	Castillo JR, Peters SP and Busse WW: Asthma exacerbations: Pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract. 5:918–927. 2017. View Article : Google Scholar : PubMed/NCBI
24	Yeo SH, Aggarwal B, Shantakumar S, Mulgirigama A and Daley-Yates P: Efficacy and safety of inhaled corticosteroids relative to fluticasone propionate: A systematic review of randomized controlled trials in asthma. Expert Rev Respir Med. 11:763–778. 2017. View Article : Google Scholar : PubMed/NCBI
25	Daley-Yates PT: Inhaled corticosteroids: Potency, dose equivalence and therapeutic index. Br J Clin Pharmacol. 80:372–380. 2015. View Article : Google Scholar : PubMed/NCBI
26	Bai TR, Vonk JM, Postma DS and Boezen HM: Severe exacerbations predict excess lung function decline in asthma. Eur Respir J. 30:452–456. 2007. View Article : Google Scholar : PubMed/NCBI
27	Cortese S, Gatta A, Della Valle L, Mangifesta R, Di Giampaolo L, Cavallucci E, Petrarca C, Paganelli R and Di Gioacchino M: Fluticasone/formoterol association favors long-lasting decrease in bronchial reactivity to methacholine and weekly PEF variability. Int J Immunopathol Pharmacol. 29:769–774. 2016. View Article : Google Scholar : PubMed/NCBI